Skip to main content

Oncolytics Biotech Value Stock - Dividend - Research Selection

Oncolytics biotech

ISIN: CA6823108759 , WKN: A2JMW5

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks

2026-05-04
Oncolytics shares rise as pelareorep shows 19.5-month response durability and higher response rates in colorectal cancer study.

Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants

2026-05-04
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate

Oncolytics Biotech Aligns With FDA On Pivotal Trial Design For Pelareorep In Advanced Anal Cancer

2026-04-27
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinomaPivotal study expected to focus on patients in a post-standard-of-care patient population with no

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

2026-04-25
Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer. Check out why ONCY stock is a buy.

12 Health Care Stocks Moving In Friday's After-Market Session

2026-04-10

CORRECTION: Oncolytics Biotech Launches Up To $75M At-the-Market Equity Offering With Jefferies To Fund Clinical Development And Operations

2026-04-06
On April 6, 2026, Oncolytics Biotech Inc. (the "Company") entered into an Open Market Sale Agreement (the "Sales Agreement") with Jefferies LLC (the "Agent"), pursuant to which the Company may offer and sell from time to

Oncolytics Biotech Schedules FDA Type C Meeting On April 16

2026-04-06
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to

Oncolytics Biotech Initiates Metastatic Colorectal Cancer Phase 2 Study That Will Be Referred To As REO 033

2026-03-02
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS

Oncolytics Biotech Concludes Patient Enrollment In GOBLET Trial

2026-02-24
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that it has concluded enrollment in the GOBLET study, having